Excitatory Amino Acid Receptors, Oxido-reductive Processes and Brain Oedema Following Transient Ischaemia in Gerbils
A key mechanism of brain injury after cerebral ischaemia is supposed to be the iron-dependent formation of highly reactive oxygen free radicals initiated by the intracellular accumulation of calcium and promoted by the excess release of glutamate. Oxido-reductive processes (formation of superoxide radicals and lipid peroxidation) are mediated through NMDA-receptors, while non-NMDA receptors, associated with (or being a part of) Na,K-ATPase, are responsible for postischaemic brain swelling. The hypothesis was put forward for consideration that release of glutamate (and other related endogenous excitatory amino acids) due to depolarization in the early minutes of ischaemia and (non)-NMDA antagonists may have roles in the development and prevention of metabolic brain impairment and cytotoxic oedema, respectively, in the ischaemic state.
KeywordsBrain Oedema NMDA Antagonist Transient Ischaemia Excitatory Amino Acid Receptor Excitatory Amino Acid Release
Unable to display preview. Download preview PDF.
- 1.Arvin B, Neville FL, Pan J, Roberts JP (1989) 2-chloroadenosine attenuates kainic acid-induced toxicity within the rat striatum: relationship to release of glutamate and Ca’ influx. Br J Pharmacol 98: 225–235Google Scholar
- 2.Auclair C, Voisin E (1985) Handbook of methods for oxygen radical research. CRC Press, Florida, pp 123–132Google Scholar
- 5.Elliot KAC, Jasper H (1949) Measurement of experimentally induced brain swelling and shrinkage. Am J Pathol 157: 122–129Google Scholar
- 8.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 952–958Google Scholar
- 10.Murphy T, Parikh A, Schnaar R, Coyle J (1989) Arachidonic acid metabolism in glutamate neurotoxicity. In: Boland B, Culliman J, Stiefel R (eds) Ann New York Acad Sci 559: 474–477Google Scholar
- 11.Shimoyama M, Kito S, Inokawa M (1988) Effects of 3-methyl1-(5-oxohexyl)-7-propylxanthine on the in vivo release of monoamines studied by intracerebral dialysis. Drug Res 38: 243–247Google Scholar